Lung cancer

Chemotherapy

PD-L1

Cancer research

Biochemistry

Immunotherapy

Biology

Apoptosis

Atezolizumab

Programmed cell death

Cancer

Internal medicine

Cytotoxic T cell

Cytotoxicity

Oncology

In vitro

Nivolumab

Medicine

New England Journal of Medicine

Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy.

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer